arrow
P

Peter Schmid

Queen Mary University of London
H指数:47
被引数:1.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

HER2阳性早期乳腺癌化疗降级治疗的5年结局及PHERGain随机II期试验中的探索性循环肿瘤DNA分析

2026-10-290
OAAI
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial

一线durvalumab联合曲妥珠单抗deruxtecan治疗局部晚期不可切除或转移性,激素受体阴性,HER2-low乳腺癌的女性: 多中心,开放标签,1b/2期海棠平台试验

2026-06-080
OAAI
PHLDA1 Mediates Drug Resistance in Receptor Tyrosine Kinase-Driven Cancer ( vol 22, pg 2469, 2018)

PHLDA1介导受体酪氨酸激酶驱动的癌症中的药物抵抗 (vol 22, pg 2469, 2018)

2026-06-010
OAAI
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor

III期ADELA试验研究设计:在既往内分泌治疗联合CDK4/6抑制剂进展后的ESR1突变ER+/HER2–晚期乳腺癌中,评估elacestrant联合或联合everolimus的疗效

2026-01-010
OAAI
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial☆

在PARSIFAL试验中,对内分泌敏感、激素受体阳性/HER2阴性晚期乳腺癌患者使用palbociclib联合fulvestrant或letrozole的延长随访研究☆

2025-07-010
PRE
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

TROPION-Breast05:一项关于Dato-DXd联合或不联合durvalumab与化疗联合pembrolizumab治疗PD-L1高表达局部复发不可手术或转移性三阴性乳腺癌的随机III期研究

2025-04-170
OA
TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2-breast cancer

TROPION-Breast04:一项针对治疗初治早期三阴性或HR低表达/HER2阳性乳腺癌患者的新辅助达托妥单抗德鲁替康(Dato-DXd)联合度伐利尤单抗,随后进行辅助度伐利尤单抗与标准护理对照的随机III期研究

2025-02-051
OA
Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC

pembrolizumab联合化疗治疗亚洲晚期TNBC患者的随机355研究结果

2024-09-120
OAAI
MiRaDor: A proof-of- concept study of treatment efficacy by monitoring Minimal Residual Disease (MRD) using circulating tumor DNA (ctDNA) in hormone receptor-positive/HER2-negative (HR+/HER2-) early breast cancer (EBC)
2024-05-020
PRE
3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial
LANCET
IF88.5
2024-04-0116
PRE
Validation of a genomic assay in early-stage HER2+breast cancer (BC) treated with trastuzumab and pertuzumab (HP): A correlative analysis from PHERGain phase II trial
2023-10-011
PRE
Aromatase inhibition plus/minus Src inhibitor saracatinib (AZD0530) in advanced breast cancer therapy (ARISTACAT): a randomised phase II study
2023-03-027
OAAI
Combined biomarker analysis for prediction of pathological complete response (pCR) after 12 weeks of pembrolizumab plus trastuzumab plus pertuzumab in HER2-enriched early breast cancer: Keyriched-1 trial
2023-03-010
PRE
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

曲妥珠单抗Deruxtecan在先前治疗的HER2-Low晚期乳腺癌中的应用

2022-07-071.3K
OA
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer

ESMO转移性乳腺癌患者诊断、分期和治疗的临床实践指南

2021-12-01647
OAAI
Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (METRIC): a randomized multicenter study
2021-05-2036
OAAI